Avicanna Inc.

Avicanna Inc. is a commercial-stage international biopharmaceutical company headquartered in Toronto, Canada, dedicated to the research, development, and commercialization of evidence-based cannabinoid-based products and formulations. Founded in 2016, the company's core mission is to integrate cannabinoid-based medicine into standard healthcare, focusing strictly on medical and pharmaceutical applications rather than the recreational cannabis market. [1, 4, 6, 7, 9, 10, 11, 16, 19, 23, 31, 32]

Avicanna's scientific platform has led to the commercialization of over thirty proprietary products across four key business pillars. These include the RHO Phyto™ medical cannabis formulary, offering diverse cannabinoid-based products in various delivery forms, and MyMedi.ca, a medical cannabis care platform providing products, pharmacist-led support, and educational resources. The company also maintains a pharmaceutical pipeline developing indication-specific cannabinoid drug candidates for dermatology, pain management, and neurological disorders, with its first pharmaceutical preparation, Trunerox™, approved in Colombia. Additionally, through its majority-owned subsidiary Santa Marta Golden Hemp SAS (SMGH), Avicanna supplies Active Pharmaceutical Ingredients (CBD, THC, CBG) to international partners for use in food, cosmetics, medical, and pharmaceutical products. [1, 7, 8, 9, 10, 15, 16, 29, 31, 33]

Led by CEO Aras Azadian, Avicanna has recently reported strong financial performance, including triple-digit growth in gross profit and a significant revenue surge in 2023, with Q1 2024 being noted as their "best quarter." [2, 8, 18, 22] The company secured an exclusive pharma supply deal for proprietary topical products in six European countries in 2024 and received a US patent for topical cannabinoid compositions for clear skin in August 2025. [2, 8] Avicanna has also restructured its Board of Directors in April 2026 to align with its evolving corporate strategy and welcomed the initial U.S. rescheduling of medical cannabis, which is anticipated to facilitate its entry into the U.S. market. [13, 20, 25, 27, 31]